PE20010918A1 - Forma cristalina de eplerenona - Google Patents

Forma cristalina de eplerenona

Info

Publication number
PE20010918A1
PE20010918A1 PE2000001302A PE0013022000A PE20010918A1 PE 20010918 A1 PE20010918 A1 PE 20010918A1 PE 2000001302 A PE2000001302 A PE 2000001302A PE 0013022000 A PE0013022000 A PE 0013022000A PE 20010918 A1 PE20010918 A1 PE 20010918A1
Authority
PE
Peru
Prior art keywords
eplerenone
refers
crystal
crystalline
crystal form
Prior art date
Application number
PE2000001302A
Other languages
English (en)
Spanish (es)
Inventor
Thomas B Borchardt
Chris Y Yan
Subhash Desai
Leonard J Ferro
Scott Ganser
Henry T Gaud
Clay R Little
Partha S Mudipalli
Barton Kathleen P P
Mark A Pietz
Daniel R Pilipauskas
Yuen-Lung L Sing
Glenn L Stahl
Joseph J Wieczorek
Marlon V Carlos
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20010918A1 publication Critical patent/PE20010918A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
PE2000001302A 1999-12-08 2000-12-06 Forma cristalina de eplerenona PE20010918A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16970799P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08

Publications (1)

Publication Number Publication Date
PE20010918A1 true PE20010918A1 (es) 2001-09-10

Family

ID=27558586

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001302A PE20010918A1 (es) 1999-12-08 2000-12-06 Forma cristalina de eplerenona

Country Status (18)

Country Link
US (1) US20090149431A1 (https=)
EP (1) EP1175434A2 (https=)
JP (2) JP4219105B2 (https=)
KR (1) KR100584104B1 (https=)
CN (1) CN100413881C (https=)
AR (1) AR074665A2 (https=)
AU (1) AU2041101A (https=)
BR (1) BR0008054A (https=)
CA (1) CA2362845A1 (https=)
CO (1) CO5280205A1 (https=)
EA (1) EA008449B1 (https=)
HU (1) HUP0201457A3 (https=)
IL (2) IL144757A0 (https=)
MY (1) MY143571A (https=)
NO (1) NO20013857L (https=)
NZ (1) NZ513962A (https=)
PE (1) PE20010918A1 (https=)
WO (1) WO2001041535A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
CN113173968A (zh) * 2021-03-19 2021-07-27 江苏康思尔医药科技有限公司 一种依普利酮的纯化方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5981744A (en) * 1995-12-11 1999-11-09 G. D. Searle And Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
EA008449B1 (ru) 2007-06-29
JP4219105B2 (ja) 2009-02-04
AR074665A2 (es) 2011-02-02
CA2362845A1 (en) 2001-06-14
US20090149431A1 (en) 2009-06-11
JP2003515611A (ja) 2003-05-07
IL144757A (en) 2007-07-24
AU2041101A (en) 2001-06-18
IL144757A0 (en) 2002-06-30
WO2001041535A9 (en) 2002-07-04
BR0008054A (pt) 2002-03-12
CN1433427A (zh) 2003-07-30
EP1175434A2 (en) 2002-01-30
NO20013857D0 (no) 2001-08-08
HK1057220A1 (zh) 2004-03-19
CO5280205A1 (es) 2003-05-30
CN100413881C (zh) 2008-08-27
NZ513962A (en) 2004-08-27
NO20013857L (no) 2001-10-08
HUP0201457A3 (en) 2003-07-28
KR20020003192A (ko) 2002-01-10
JP2007016043A (ja) 2007-01-25
EA200100869A1 (ru) 2002-04-25
MY143571A (en) 2011-05-31
KR100584104B1 (ko) 2006-05-30
HUP0201457A2 (en) 2002-08-28
WO2001041535A2 (en) 2001-06-14
WO2001041535A3 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
PE20010918A1 (es) Forma cristalina de eplerenona
CO5770096A1 (es) Forma cristalina beta de clorhitrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
Xi et al. Reversible dendritic‐crystal‐reinforced polymer gel for bioinspired adaptable adhesive
CN102660231B (zh) 一种无机相变材料及其制备方法
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CO5770095A1 (es) Forma cristalina gamma-d del clorhitrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO5840253A1 (es) Forma cristalina delta d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
PE20010917A1 (es) Forma cristalina de eplerenona que muestra un aumento en la velocidad de disolucion
PE20010911A1 (es) Forma en estado solido de celecoxib que tiene una biodisponibilidad mejorada
PE20081396A1 (es) Compuesto cristalino del 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
DK1598333T3 (da) Fremgangsmåde til fremstilling af (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutan og syreadditionssalte heraf samt anvendelse til syntese af ivabradin og syreadditionssalte heraf med farmaceutisk acceptable syrer
ES2298327T3 (es) Preparacion de una forma polimorfica de un derivado de tiazolidinadiona.
US4409030A (en) Material for destroying concrete structures
AR016161A1 (es) Procedimiento para preparar un hidrato de la sal de acido maleico de 5-[4- [2-(n-metil-n(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona.
CR8800A (es) Regimenes y equipos anticonceptivos de antagonistas del receptor de progesterona
Chatterji Aspects of generation of destructive crystal growth pressure
DE60221376D1 (de) Klebstoffzusammensetzung und klebegegenstand
CN102295466A (zh) 二元溶液结晶体为模板制备多孔陶瓷的方法
Zhang et al. Can crystalline phases be self-healing sealants for solid oxide fuel cells?
ES2204358T1 (es) Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
HRP20010630B1 (hr) Derivati 4-heterociklil-sulfonamidil-6-metoksi-5-(2-metoksi-fenoksi)-2-piridil-pirimidina, njihova proizvodnja i upotreba kao endotelin receptor antagonista
JPS5865895A (ja) 岩石、コンクリ−ト等の破砕用補助具及びそれを用いた破砕剤と破砕方法
Wood et al. Characterization of latent heat-releasing phase change materials for dermal therapies
Liu et al. Effect of different fluxing agents on basic performance of quartz porous ceramics for molten salt infiltrating spontaneously
CN106365520A (zh) 一种储能砖组份及制备方法

Legal Events

Date Code Title Description
FC Refusal